# Novel Interventions in HIV-1 Infection

> **NCT01130376** · PHASE1 · TERMINATED · sponsor: **Imperial College London** · enrollment: 12 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **BIOLOGICAL:** GTU-MultiHIV B clade vaccine1mg
- **DRUG:** Interleukin-2
- **DRUG:** GM-CSF
- **DRUG:** Growth Hormone

## Key facts

- **NCT ID:** NCT01130376
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Data from the 12 patients recruited has now been analysed, and it has been determined that it is sufficient to meet the study objectives.
- **Last updated:** 2013-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01130376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01130376, "Novel Interventions in HIV-1 Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01130376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*